Antibodies to HTEEB42 protein
    1.
    发明授权
    Antibodies to HTEEB42 protein 失效
    HTEEB42蛋白的抗体

    公开(公告)号:US07781176B2

    公开(公告)日:2010-08-24

    申请号:US11744695

    申请日:2007-05-04

    Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

    Abstract translation: 本发明涉及含有编码这些蛋白质的基因的编码区的新的人分泌蛋白和分离的核酸。 还提供了用于产生人分泌蛋白质的载体,宿主细胞,抗体和重组方法。 本发明还涉及用于诊断和治疗与这些新型人分泌蛋白相关的疾病,病症和/或病症的诊断和治疗方法。

    Human tumor necrosis factor receptors TR21 and TR22
    10.
    发明申请
    Human tumor necrosis factor receptors TR21 and TR22 审中-公开
    人肿瘤坏死因子受体TR21和TR22

    公开(公告)号:US20050090436A1

    公开(公告)日:2005-04-28

    申请号:US10620562

    申请日:2003-07-17

    Abstract: The present invention relates to two novel proteins, TR21 and TR22, which are members of the tumor necrosis factor (TNF) receptor. In particular, isolated nucleic acid molecules are provided encoding the human TR21 and TR22 protein. TR21 and TR22 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 and TR22 activity; and methods of treating immune disorders by administering TR21 and TR22 polynucleotides, polypeptides, agonists, and antagonists.

    Abstract translation: 本发明涉及作为肿瘤坏死因子(TNF)受体成员的两种新型蛋白质TR21和TR22。 特别地,提供编码人TR21和TR22蛋白的分离的核酸分子。 还提供TR21和TR22多肽,载体,宿主细胞和用于制备它们的重组方法。 本发明还涉及用于鉴定TR21和TR22活性的激动剂和拮抗剂的筛选方法; 以及通过施用TR21和TR22多核苷酸,多肽,激动剂和拮抗剂来治疗免疫疾病的方法。

Patent Agency Ranking